-$0.65 EPS Expected for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) This Quarter

Analysts predict that Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Rating) will announce earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Tarsus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.96). Tarsus Pharmaceuticals reported earnings per share of $0.29 in the same quarter last year, which suggests a negative year over year growth rate of 324.1%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tarsus Pharmaceuticals will report full year earnings of ($3.37) per share for the current financial year, with EPS estimates ranging from ($4.26) to ($2.40). For the next fiscal year, analysts forecast that the business will report earnings of ($4.96) per share, with EPS estimates ranging from ($5.28) to ($4.32). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tarsus Pharmaceuticals.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 25.85% and a negative net margin of 184.14%. The business had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $7.11 million.

Several analysts recently commented on TARS shares. Zacks Investment Research upgraded Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 24th. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $55.00 to $66.00 in a report on Monday, May 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Tarsus Pharmaceuticals in a report on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $48.00.

In other news, Director Michael Ackermann bought 100,000 shares of the stock in a transaction dated Thursday, May 5th. The shares were bought at an average cost of $13.50 per share, with a total value of $1,350,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $1,350,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Vivo Capital Ix, Llc sold 41,800 shares of the company’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $15.19, for a total value of $634,942.00. Following the transaction, the insider now directly owns 2,945,531 shares in the company, valued at $44,742,615.89. The disclosure for this sale can be found here. 33.08% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the company. BlackRock Inc. grew its holdings in Tarsus Pharmaceuticals by 0.7% during the third quarter. BlackRock Inc. now owns 441,620 shares of the company’s stock worth $9,519,000 after buying an additional 3,264 shares in the last quarter. Morgan Stanley bought a new stake in Tarsus Pharmaceuticals during the second quarter worth $241,000. Bank of America Corp DE grew its holdings in Tarsus Pharmaceuticals by 84.8% during the fourth quarter. Bank of America Corp DE now owns 10,662 shares of the company’s stock worth $240,000 after buying an additional 4,891 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth $202,000. Finally, UBS Group AG grew its holdings in Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after buying an additional 1,142 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

TARS stock traded up $0.50 during trading on Tuesday, hitting $14.49. The company had a trading volume of 195,740 shares, compared to its average volume of 109,902. The business has a 50-day moving average of $16.27 and a 200-day moving average of $19.86. Tarsus Pharmaceuticals has a one year low of $10.80 and a one year high of $39.08. The stock has a market cap of $300.33 million, a PE ratio of -6.68 and a beta of 1.45. The company has a current ratio of 14.18, a quick ratio of 14.18 and a debt-to-equity ratio of 0.13.

Tarsus Pharmaceuticals Company Profile (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

See Also

Get a free copy of the Zacks research report on Tarsus Pharmaceuticals (TARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.